This has been investigated in clinical trials with Erbitux® (an inhibitor of epidermal growth factor, EGFR) and FOLFIRI in colorectal cancer (NCT00719199) or with Erbitux®, 5-fluorouracil (5-FU), and cisplatin in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) (NCT01360827), and with erlotinib and bevacizumab in non-small-cell lung carcinoma (NSCLC) (NCT00633529). This evidence concerns the gene EGF and non-small cell lung carcinoma.